Opinion|Videos|May 30, 2025
Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how the PALOMA-3 study demonstrated that subcutaneous amivantamab is noninferior to intravenous (IV) administration with significantly lower infusion-related reaction (IRR) rates (13% vs 66%), shorter administration time (5 minutes vs 5 hours), higher patient-reported convenience (85% vs 35%), and improved clinical outcomes, making it potentially preferable for most eligible patients once FDA approved.
Advertisement
Episodes in this series
Subcutaneous vs IV Amivantamab
- PALOMA-3 study findings:
- Similar efficacy: 30% response rate (subcutaneous) vs 33% (IV)
- Improved PFS: 6.1 months (subcutaneous) vs 4.3 months (IV) in heavily pretreated population
- Significantly reduced IRRs: 13% (subcutaneous) vs 66% (IV)
- Fewer venous thromboembolism events with subcutaneous administration
- Operational advantages:
- Dramatically reduced administration time: 5 minutes (subcutaneous) vs 5 hours (IV)
- Improved infusion chair turnover
- No split dosing required (unlike IV which requires day 1/day 2 split)
- Patient preference: 85% rated subcutaneous as convenient vs 35% for IV
- Not yet FDA approved outside clinical trials
Advertisement
Related to this article
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5